Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

Division of Johnson & Johnson
www.janssenpharmaceuticalsinc.com

Latest From Ultragenyx Pharmaceutical Inc.

Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up

The latest drug development news and US FDA highlights from our Performance Tracker.

Complete Response Letters Drug Review

Pipeline Watch: Phase III Progress With Abemaciclib, Esketamine

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Dismay With Veliparib, Tarextumab, House Dust Mite Allergens

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?

Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.

Clinical Trials Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register